Construction method and application of animal model of true microphthalmia

Through CRISPR/Cas9 technology, a p.P164S point mutation of the MFRP gene was introduced in mice, and a true small eyeball animal model was constructed, which solved the problem that the existing model could not simulate genetic mutation in human patients, and achieved research that was closer to human diseases and Therapeutic exploration.

CN118272448BActive Publication Date: 2024-11-26PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410414749.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-08
Publication Date
2024-11-26
Estimated Expiration
2044-04-08

AI Technical Summary

Technical Problem

Most of the existing animal models are gene mutation mouse models related to MFRP knockout, frameshift, fragment deletion and insertion. The MFRP true small eyeball animal model lacks point mutation, which cannot effectively simulate the genetic mutation of human patients, limiting the true small Research and treatment exploration of eye diseases.

Method used

Through CRISPR/Cas9 gene editing technology, a p.P164S point mutation of the MFRP gene was introduced in mice, and an animal model with true small eyeball clinical manifestations was constructed to simulate the development and development of human diseases.

Benefits of technology

The constructed model shows symptoms such as short axial length and high hyperopia that are consistent with human clinical cases, providing an animal model closer to the patient's condition, and enhancing the reference value of real small eye diseases and drug screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118272448B_ABST
    Figure CN118272448B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for constructing an animal model of true microphthalmia and its application, which comprises: mutating the MFRP gene of a target animal by genetic engineering technology to obtain an animal model of MFRP gene p.P164S point mutation. The present invention constructs a mouse model of true microphthalmia by the above method, and the acquisition of the model can effectively simulate the clinical phenotype of true microphthalmia in humans, which is helpful to explore the specific regulatory mechanism of MFRP gene point mutation on mammalian eye development and high hyperopia, and can provide an animal model closer to the patient phenotype for subsequent drug screening and clinical research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gene engineering technology, and in particular to a method for constructing a true microphthalmia animal model and an application thereof. Background Art

[0002] Nanophthalmos is a hereditary eye disease with developmental abnormalities. It is caused by the cessation of eyeball development after the closure of the embryonic fissure. The axial length of the eye is ≤20.5mm, the volume of the eyeball is smaller than normal, about 2 / 3 of the normal eyeball, without other eye deformities and systemic lesions. It is a type of congenital microphthalmia. Clinically, true microphthalmia is often manifested as small cornea, short anterior-posterior diameter of the eyeball, high hyperopia, etc., without other eye abnormalities. The prevalence of congenital microphthalmia is 0.008% to 0.032%, which is a common hereditary eye disease. However, there are mostly sporadic case reports, and reports of familial hereditary patients are rare. Among them, the pathogenic mechanism of MFRP gene-related true microphthalmia is not clear, so more detailed pathogenic mechanism research is still needed.

[0003] The study of ocular genetic diseases cannot be separated from animal models, and the existing animal models are mostly MFRP knockout, frameshift, fragment deletion and insertion related gene mutation mouse models, and there are few MFRP animal models with point mutations. However, in patients, point mutations are the most common type of mutations. The homozygous point mutation animal model of true microphthalmia is closer to the patient's genetic mutation situation, which can enrich the research on the mechanism of true microphthalmia disease development and the exploration of treatment methods. At present, there is still a lack of relevant clinical manifestations of patients with point mutation MFRP true microphthalmia animal models.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] The purpose of the present invention is to provide a method for constructing an animal model of true microphthalmia and its application. The animal model has the manifestations or symptoms of true microphthalmia, and provides an animal model basis for the study of the pathophysiological mechanism of true microphthalmia, the screening of related gene therapy drugs, etc.

[0006] The present invention is achieved in that:

[0007] In a first aspect, the present invention provides a method for constructing a true microphthalmia animal model, comprising: using genetic engineering technology to mutate the MFRP gene of a target animal to obtain a MFRP p.P164S point mutation animal model.

[0008] The MFRP gene is located in the human chromosome 11q23.3 region and encodes a transmembrane protein composed of 579 amino acids - membrane curling-related protein. Its cysteine-rich region forms an extracellular curling-like structure, recognizes the curling Wnt receptor, and mediates cell behavior and eye development. MFRP protein is expressed in the ciliary epithelium and retinal pigment epithelium, and is involved in the maintenance of the outer segments of embryonic retinal photoreceptors. Studies have shown that MFRP gene mutations are associated with true microphthalmia (short axial length, small cornea, narrow anterior chamber). Most of the existing animal models are MFRP knockout, frameshift, fragment deletion and insertion-related gene mutation mouse models, and there are few MFRP animal models with point mutations. However, point mutations are the most common type of mutation in patients. In order to obtain an animal model that is closer to the real disease, the inventors of the present invention constructed the above-mentioned MFRP gene point mutation animal model, which shows a series of typical human true microphthalmia clinical manifestations such as shorter axial length and high hyperopia compared with the wild type from birth, which is consistent with the results of human clinical cases.

[0009] Currently, 14 exons have been identified for the MFRP gene, of which the ATG start codon is located in exon 1 and the TGA stop codon is located in exon 13 (transcript: 201-ENSMUST00000034654). p.P164 is located in exon 5.

[0010] In some embodiments, the genetic engineering technology includes gene editing technology, and the gene editing technology is selected from at least one of DNA homologous recombination technology, CRISPR / Cas9 technology, ZFN technology and TALEN technology.

[0011] In some embodiments, the gene editing technology is CRISPR / Cas9 technology.

[0012] In some embodiments, the target animal is a non-human mammal.

[0013] In some embodiments, the non-human mammal is selected from any one of a mouse, a rat, a horse, a pig, a monkey, a dog, and a monkey.

[0014] In some embodiments, the target animal is a mouse.

[0015] In some embodiments, the method of using CRISPR / Cas9 technology to mutate the MFRP gene of mice includes: microinjecting Cas9 mRNA, gRNA and Donor Oligo into the fertilized eggs of donor mice; wherein the gRNA is as shown in SEQ ID NO.1-2, and the nucleotide sequence of Donor Oligo is as shown in SEQ ID NO.3.

[0016] When using CRISPR / Cas9 technology to edit the target gene, its gRNA is an important dependency of the gene editing effect, and not any gRNA can achieve the gene editing effect. The present invention uses SEQ ID NO.1-2 as the target sequence of gRNA through creative labor, and in the presence of suitable Cas9 mRNA and Donor Oligo, achieves the target mutation p.P164S (CCT→TCT) of the MFRP gene, thereby obtaining an animal model with a P164S mutation in the MFRP protein, and exhibits the corresponding symptoms of true microphthalmia.

[0017] Among them, the comparison between the mouse MFRP gene (GenBank accession number: NM_147126.3; Ensembl: ENSMUSG00000034739) and the human MFRP gene is as follows: Figure 1 As shown, the gene is located on mouse chromosome 9. The present invention uses the 5th exon of the gene as the target site and designs the above-mentioned gRNA and Donor Oligo.

[0018] In some embodiments, the method of using CRISPR / Cas9 technology to mutate the MFRP gene of mice also includes: transplanting fertilized eggs into the oviducts of surrogate mice to obtain F0 generation mice, and identifying the F0 generation mice to obtain positive F0 mice, and then mating the positive F0 mice with wild-type mice to obtain F1 generation heterozygous mice, and then mating the F1 generation heterozygous mice with each other, and identifying the obtained F2 generation mice to obtain homozygous mutant mice, which is a true microphthalmia animal model.

[0019] In a second aspect, the present invention provides a method for breeding a true microphthalmia animal model, comprising: mating the true microphthalmia animal models obtained by the above-mentioned construction method with each other.

[0020] After obtaining the primary true microphthalmia model by the above-mentioned construction method, in order to obtain a larger number of offspring true microphthalmia models, those skilled in the art may easily think of a breeding method in which the primary true microphthalmia models are mated with each other to obtain a larger number of offspring true microphthalmia models. This method of breeding true microphthalmia models also falls within the scope of protection of the present invention.

[0021] In a third aspect, the present invention provides a true microphthalmia animal model obtained by the above-mentioned method for constructing a true microphthalmia animal model.

[0022] In a fourth aspect, the present invention provides application of the above-mentioned true microphthalmia animal model in the study of true microphthalmia disease.

[0023] In a fifth aspect, the present invention provides the use of the above-mentioned true microphthalmia animal model in screening drugs for treating true microphthalmia disease.

[0024] In some embodiments, the above application includes: administering a candidate drug to the above animal model of true microphthalmia, and if the animal model of true microphthalmia undergoes at least one of the following changes before and after the administration of the candidate drug, it indicates that the candidate drug can be used as a drug for preventing or treating true microphthalmia:

[0025] (1) After administration of the candidate drug, the axial length of the eye in the true microphthalmos model increases compared to before administration of the candidate drug;

[0026] (2) After administration of the candidate drug, the retina of the fundus of the true microphthalmia model becomes thinner compared to before administration of the candidate drug;

[0027] (3) After administration of the candidate drug, the refractive power of the true microphthalmia model is reduced compared to before administration of the candidate drug.

[0028] The present invention has the following beneficial effects:

[0029] (1) The present invention uses CRISPR / Cas9 gene mutation technology to construct a true microphthalmia mouse model with MFRP p.P164S gene point mutation. By using gene site-directed mutagenesis, the mouse undergoes changes at the genomic level, thereby making the disease in the model closer to the occurrence and development of the real disease, and the research results are more valuable for reference;

[0030] (2) The microphthalmia mouse model constructed by the present invention simulates microphthalmia. The model can effectively simulate the clinical phenotype of human microphthalmia, help to explore the specific regulatory mechanism of MFRP gene point mutation on mammalian eye development and high hyperopia, and provide an animal model that is closer to the patient phenotype for subsequent drug screening and clinical research. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0032] Figure 1 A comparison diagram of the nucleotide and amino acid sequences of the MFRP gene in humans and mice in the present invention;

[0033] Figure 2 This is a schematic diagram of the strategy for constructing MFRP gene point mutation mice in Example 1;

[0034] Figure 3This is the electrophoresis result of the homozygous mutant mice in Example 1;

[0035] Figure 4 The figure is the sequencing result of the homozygous mutant mouse in Example 1;

[0036] Figure 5 This is the OCT examination result of the mouse in Example 2;

[0037] Figure 6 This is a comparison diagram of HE staining of mice in Example 2;

[0038] Figure 7 Comparison of the refractive index test results of mice in Example 2;

[0039] Figure 8 Comparison of the mouse axial length detection results in Example 2. DETAILED DESCRIPTION

[0040] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0041] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0042] Example 1

[0043] In this example, CRISPR / Cas9 technology was used to introduce the target point mutation MFRP p.P164S by homologous recombination repair; Figure 2 As shown, the homologous recombination region for achieving the site-directed mutagenesis is exon 5 of the MFRP gene, and the P164S mutation of the MFRP gene is achieved by introducing a C>T mutation in exon 5.

[0044] In this example, C57BL / 6J mice were used to construct an MFRP p.P164S site-directed mutation animal model; the C57BL / 6J mice were purchased from Saiye Biotechnology Co., Ltd. and were 4 weeks old.

[0045] The specific construction method is as follows:

[0046] (1) Design of MFRP gene CRISPR / Cas9 gRNA and donor oligonucleotide:

[0047] According to the sequence of mouse MFRP gene (GenBank accession number: NM_147126.3; Ensembl: ENSMUSG00000034739) and the mutation C492T to be introduced (the sequence before and after the mutation is shown in SEQ ID NO.4-5), two gRNA sequences and donor oligonucleotides (with a targeting sequence and 120 bp homologous sequences on both sides) were designed. The specific sequences are shown below:

[0048] gRNA1: GGTAGAGGTCTGGGTAGTTA-GGG (SEQ ID NO. 1);

[0049] gRNA 2:GGGTAGAGGTCTGGGTAGTT-AGG (SEQ ID NO. 2);

[0050] Donor oligo:

[0051] CCCCAATCCCCTGCAGCCTGTGGAGGCCTCCTTCCTGGTCCCAGT GGTTTCTTCAGCAGCTCTAACTACCCAGACCTCTACCCACCCCTCAGC CACTGTGTCTGGCATATCCAGGTAGCCGCG (SEQ ID NO. 3);

[0052] Nucleotide sequence before target mutation:

[0053] CCCCAATCCCCTGCAGCCTGTGGAGGCCTCCTTCCTGGTCCCAGT GGTTTCTTCAGCAGC(CCT)AACTACCCAGACCTCTACCCACCCCTCAG CCACTGTGTCTGGCATATCCAGGTAGCCGCG(SEQ ID NO.4);

[0054] Nucleotide sequence after target mutation:

[0055] CCCCAATCCCCTGCAGCCTGTGGAGGCCTCCTTCCTGGTCCCAGT GGTTTCTTCAGCAGC(TCT)AACTACCCAGACCTCTACCCACCCCTCAG CCACTGTGTCTGGCATATCCAGGTAGCCGCG(SEQ ID NO.5);

[0056] The nucleotides in brackets are the 3 nucleotides of the mutated amino acid.

[0057] (2) Microinjection

[0058] The in vitro transcribed gRNA and Cas9 mRNA were mixed with Donor oligo, and after adjusting the injection concentration, the mixture was microinjected into the fertilized eggs of C57BL / 6J mice using a microinjector. The surviving fertilized eggs were then transplanted into the uterus of pseudopregnant mother mice until the F0 generation of mice were born.

[0059] (3) Identification of F0 generation mice

[0060] The mice were identified after birth, their tails were collected, genomic DNA was extracted, and PCR reaction was performed using this as a template. PCR electrophoresis and sequencing were then used to identify whether there was a base mutation at the target site.

[0061] The genomic DNA was extracted using TaKaRa MiniBEST Universal Genomic DNA Extraction kit (Ver.5.0_Code No.9765) in the following steps:

[0062] 1) In a microcentrifuge tube, add 180 μL of buffer GL, 20 μL of proteinase K, and 10 μL of RNase A per tail piece (2-5 mm);

[0063] 2) Incubate at 56°C overnight;

[0064] 3) Centrifuge at 12,000 rpm for 2 min to remove impurities;

[0065] 4) Add 200 μL of buffer GB and 200 μL of anhydrous ethanol and mix thoroughly;

[0066] 5) Place the spin column in the collection tube. Apply the sample to the spin machine and centrifuge at 12000 rpm for 2 minutes;

[0067] 6) Add 500 μL of buffer WA to the spin column and centrifuge at 12000 rpm for 1 min;

[0068] 7) Add 700 μL of buffer albumin to the spin column and centrifuge at 12,000 rpm for 1 min;

[0069] 8) Repeat step 7);

[0070] 9) Place the spin column in a collection tube and centrifuge at 12,000 rpm for 2 min;

[0071] 10) Place the spin column in a new 1.5 ml test tube, add 50-200 μL of sterile water or elution buffer to the center of the column membrane, and let the column stand for 5 minutes;

[0072] 11) To elute the DNA, centrifuge at 12000 rpm for 2 min;

[0073] 12) Obtain genomic DNA.

[0074] Primers for PCR reaction system used to identify F0 generation mice:

[0075] F1:5'-GGACTACCAAGAACCCACTGC-3'

[0076] R1:5'-CGAGGGCAGTTGTGTTAATTTTCTT-3'

[0077] The PCR reaction system is as follows:

[0078]

[0079] The reaction procedure is as follows:

[0080]

[0081] The 610 bp product amplified by the above primers was used for subsequent sequencing identification, and the sequencing primer was: 5'-CGAGGGCAGTTGTGTTAATTTTCTT-3'. The F0 generation gene mutant mice were confirmed by sequencing identification.

[0082] (4) Acquisition and identification of F1 generation mice

[0083] The F0 generation mice that were correctly identified by PCR and sequencing were mated with wild-type C57BL / 6J mice to obtain F1 generation mice, and the F1 mice were then genotyped using the above identification method. The positive F1 generation heterozygous mice obtained can be stably inherited.

[0084] (5) Acquisition and identification of F2 mice

[0085] The F1 generation heterozygous mice were crossed and the resulting offspring were bred to obtain homozygous mutant and wild-type individuals. The mice with different genotypes were sequenced, and the electrophoresis results of the homozygous mutant mice were as follows: Figure 3 The sequencing results are shown in Figure 4 shown.

[0086] Example 2

[0087] Phenotypic identification was performed on the true microphthalmia mouse model constructed in Example 1, including: mouse OCT examination, eyeball HE sectioning, refractive power and axial length detection. The specific detection methods and results are as follows:

[0088] 1. OCT examination

[0089] The mice were anesthetized by intraperitoneal injection and placed on a fixed stand. Eye drops were used to keep the eyeballs moist. The OCT device was used to scan the retinal structure and take fundus photos. After obtaining the image data of the OCT scan, data analysis was performed on the retinal thickness and color.

[0090] 2. Eyeball HE slice experiment

[0091] Three mice in each group were killed by cervical dislocation, and the eyeballs were separated, the periorbital tissues were removed, and the eyeballs were fixed in eye fixative and then embedded in paraffin and sectioned.

[0092] 3. Refraction and eye axis detection

[0093] Before the experiment, the mice were instilled with tropicamide eye drops, once every 10 minutes, 20 μL each time, for a total of 4 times. The refraction was measured under ciliary muscle paralysis. After the refraction was measured with an infrared eccentric optometry instrument, 3 mice in each group were killed by cervical dislocation, the eyeballs were separated, the periorbital tissues were removed, and the axial length was measured 3 times with a micrometer, and the average value was taken.

[0094] The results of OCT examination are as follows Figure 5 As shown, by comparing the retinas of wild-type mice and the true microphthalmia mouse model constructed in Example 1, it can be found that the retina of the mouse model constructed in the present invention is thickened.

[0095] The results of HE sections of the eyeball are as follows Figure 6 As shown, by comparing the retinas of wild-type mice with the true microphthalmia mouse model constructed in Example 1, it can be proved again that the retina of the mutant mouse model is thickened.

[0096] The results of diopter are as follows Figure 7 As shown in Table 1:

[0097] Table 1 Refractive power comparison

[0098] Refraction (D) 4w 8w 12w WT 1.93 2.48 1.61 MFRP 9.66 10.04 10.08

[0099] By comparing the refractive power of wild-type mice at different growth times and the true microphthalmia mouse model constructed in Example 1, it can be seen that the refractive power of the mutant mouse model is higher, and the refractive power of the mutant mouse model is also more stable compared to the wild-type mice at different growth periods.

[0100] Axis detection Figure 8 As shown in Table 2:

[0101] Table 2 Comparison of eye axis detection results

[0102] Average axial length (inch) 2w 4w 8w WT 0.12 0.14 0.15 MFRP 0.104 0.13 0.13

[0103] It can be seen from the figure that no matter it is a wild-type or mutant mouse model, the axial length of the eye tends to increase with the extension of growth time. By comparing the axial length of the wild-type mouse with the true microphthalmia mouse model constructed in Example 1, it can be seen that the axial length value of the mutant mouse model is smaller.

[0104] In summary, through the above phenotypic identification structure, it can be concluded that the true microphthalmia mouse model with MFRP p.P164S point mutation constructed by CRISPR / Cas9 technology in the present invention shows a series of typical human true microphthalmia clinical manifestations such as shorter axial length and high hyperopia compared with the wild type, which is consistent with the results of human clinical cases, thereby proving that the true microphthalmia model constructed by the present invention is accurate and reliable.

[0105] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for constructing a true microphthalmia animal model, characterized in that: include: Gene editing technology has enabled mice to MFRP Homozygous mutation of the gene MFRP p.P164S point mutation animal model.

2. The construction method according to claim 1, characterized in that: The gene editing technology is selected from at least one of CRISPR / Cas9 technology, ZFN technology and TALEN technology.

3. The construction method according to claim 2, characterized in that: The gene editing technology is CRISPR / Cas9 technology.

4. The construction method according to claim 3, characterized in that: Using CRISPR / Cas9 technology to make mice MFRP The method for causing the homozygous mutation of a gene comprises: microinjecting Cas9 mRNA, gRNA and Donor Oligo into the fertilized egg of a donor mouse; wherein the gRNA is as shown in SEQ ID NO.1-2.

5. The construction method according to claim 4, characterized in that: The nucleic acid sequence of the Donor Oligo is shown as SEQ ID NO.

3.

6. The construction method according to claim 5, characterized in that: Using CRISPR / Cas9 technology to make mice MFRP The method for causing the homozygous mutation of the gene also includes: transplanting the fertilized egg into the oviduct of a surrogate mouse to obtain F0 generation mice, identifying the F0 generation mice to obtain positive F0 mice, and then mating the positive F0 mice with wild-type mice to obtain F1 generation heterozygous mice, and then mating the F1 generation heterozygous mice with each other, and identifying the obtained F2 generation mice to obtain homozygous mutant mice, which is a true microphthalmia animal model.

Citation Information

Patent Citations

  • Gene chip, kit comprising gene chip and application of gene chip

    CN112626193A

  • Construction method and application of retinitis pigmentosa disease animal model

    CN114752623A

  • Application of PRSS56 protein expression and enzyme activity regulation in myopia treatment

    CN115896141A

  • Construction method for animal model for retinitis pigmentosa diseases and application

    US20200375157A1

  • Gene Editing for Autosomal Dominant Diseases

    US20210017509A1